A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

S. Lekamwasam, J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. SambrookS. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl, J. E. Compston

Research output: Contribution to journalReview articleResearchpeer-review

203 Citations (Scopus)

Abstract

Summary This paper provides a framework for the development of national guidelines for the management of glucocorticoid- induced osteoporosis in men and women aged 18 years and over in whom oral glucocorticoid therapy is considered for 3 months or longer. Introduction The need for updated guidelines for Europe and other parts of the world was recognised by the International Osteoporosis Foundation and the European Calcified Tissue Society, which set up a joint Guideline Working Group at the end of 2010. Methods and results The epidemiology of GIO is reviewed. Assessment of risk used a fracture probability-based approach, and intervention thresholds were based on 10-year probabilities using FRAX. The efficacy of intervention was assessed by a systematic review.Conclusions Guidance for glucocorticoid-induced osteoporosis is updated in the light of new treatments and methods of assessment. National guidelines derived from this resource need to be tailored within the national healthcare framework of each country. © International Osteoporosis Foundation and National Osteoporosis Foundation 2012.
Original languageEnglish
Pages (from-to)2257-2276
JournalOsteoporosis International
Volume23
Issue number9
DOIs
Publication statusPublished - 1 Sep 2012

Keywords

  • Bone mineral density
  • Bone-protective therapy
  • Fracture
  • FRAX
  • Glucocorticoids

Fingerprint Dive into the research topics of 'A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis'. Together they form a unique fingerprint.

Cite this